UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
June 8, 2005
Date of Report (Date of earliest event reported)
CONNETICS CORPORATION
(Exact name of Registrant as specified in its charter)
| | | | | |
| Delaware | | 0-27406 | | 94-3173928 |
| | | | | |
(State or Other
Jurisdiction of
Incorporation) | | (Commission File No.) | | (IRS Employer Identification No.) |
3160 Porter Drive, Palo Alto, California 94304
(Address of principal executive offices, including zip code)
(650) 843-2800
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01. Other Events.
On June 8, 2005, Connetics Corporation (“Connetics”) announced that after additional discussions with the FDA it will resume development of Extina®, an investigational new drug formulation of 2% ketoconazole for the treatment of seborrheic dermatitis. The Company received a non-approvable letter for Extina in November 2004 due to insufficient clinical data. As a result of meetings between Connetics and FDA officials regarding requirements for the Extina NDA, Connetics will recommence development of Extina by initiating a final Phase III trial intended to demonstrate that Extina is superior to placebo foam. A copy of the Connetics press release regarding Extina is attached as Exhibit 99.1 and is incorporated by reference in this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
| | | | | |
| Exhibit | | |
| Number | | Description |
| | 99.1 | | | Press Release dated June 8, 2005 regarding Extina. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | CONNETICS CORPORATION |
| | | | | |
| | By: | | /s/ Sanjiv S. Dhawan |
| | | | |
| | | | Sanjiv S. Dhawan
Vice President, Corporate Counsel |
| Date: June 9, 2005 | | | | |
EXHIBIT INDEX
| | | | | |
| Exhibit | | |
| Number | | Description |
| | 99.1 | | | Press Release dated June 8, 2005 regarding Extina. |
